Skip to content
Vivo logo
← All articles

Sermorelin Results Timeline: What to Expect by Week and Month

Sermorelin Results Timeline: What to Expect by Week and Month

Abstract stages tracing a treatment timeline

Most people who respond to sermorelin report changes gradually. Sleep-related changes are described first, at roughly 1 to 4 weeks. Measurable shifts in IGF-1 are studied over 2 to 12 weeks. Body composition, skin and similar goals are discussed over several months. The published research is smaller and more mixed than many timelines suggest, and individual response depends on baseline hormone levels, dosing, sleep, nutrition and provider oversight. This guide sets out the commonly described timeline, the controlled data behind it and the checkpoints a supervising provider typically uses.

VivoExplore Provider-Supervised SermorelinVivo offers provider-supervised Sermorelin treatment, with personalized treatment selection and medication compounded by a licensed U.S. pharmacy.Explore Sermorelin care

TL;DR

  • Growth hormone (GH) rises within hours of a dose. IGF-1, the marker providers track, changes over weeks, not days.
  • Commonly described milestones are sleep changes at 1 to 4 weeks, body composition at 2 to 3 months and skin or hair at 3 to 6 months. These come from clinic and content sources, not large trials.
  • In a 1997 trial of a close sermorelin analog, IGF-1 rose by week 2, stayed elevated to about week 12 and drifted back by week 16.
  • Human evidence in healthy adults is limited, so progress is judged with baseline and follow-up labs, not by calendar alone.
  • Sermorelin from Vivo is prescribed after provider review and compounded by a licensed U.S. pharmacy: $135 per month or $339 per quarter.

Table of Contents

Why a Sermorelin Timeline Is Hard to Pin Down

Sermorelin is a growth hormone-releasing hormone (GHRH) analog. It signals the pituitary gland to release the body’s own growth hormone, which in turn prompts the liver to produce IGF-1. Because the effect passes through two hormones, results appear in layers: a fast, short pulse of GH, a slower rise in IGF-1, and only then any change that a person might notice or measure in sleep, body composition or skin.

Two further points shape every timeline.

First, sermorelin has a very short presence in the bloodstream, while the GH pulse it triggers lasts hours. Explanations of growth hormone timing after injections draw the same line between short-term pulses and changes that build over weeks. A half-life figure is therefore not a treatment calendar.

Second, the evidence base is narrow. A 2026 review in Frontiers in Endocrinology concluded that clinically meaningful benefits of sermorelin in healthy individuals remain uncertain, because the human data are limited and largely indirect. For that reason, timelines published by clinics and content sites should be read as typical patterns reported in practice, not guarantees.

The Sermorelin Timeline, Stage by Stage

The table below combines the pattern most commonly described by clinics with what controlled studies measured. Where only practice-based reports exist, the table says so.

Stage Typical description What the research supports
First hours after a dose GH pulse begins Acute GH rise is the best-documented effect
Weeks 1 to 2 Some people report sleep or recovery changes IGF-1 rose by week 2 in one older-adult trial of a sermorelin analog
Weeks 3 to 4 Sleep and focus described as steadier Practice reports; limited controlled data
Weeks 5 to 8 IGF-1 plateau; provider review Mixed: some trials show IGF-1 unchanged at 6 weeks
Months 2 to 3 Body composition changes described Controlled results are inconsistent
Months 3 to 6 Skin, hair and longer-term goals discussed; labs rechecked Skin thickness rose in one trial; other outcomes mixed

The first hours and days

GH release after an injection is the most reliable effect. The pulse peaks within the first hour and fades over several hours. Most sermorelin protocols dose in the evening, so that the pulse coincides with the body’s natural overnight GH release. The Sermorelin dosing schedule guide covers timing, frequency and cycles in more detail.

Sermorelin

In the first days, the effects people most often mention are side effects, not benefits: injection-site redness, brief flushing or a mild headache. These are usually short-lived, and the sermorelin side effects overview explains which are common and which warrant a call to the provider.

Weeks 1 to 4: sleep first, if at all

Sleep is the area most often reported as changing first, usually between week 1 and week 4. The mechanism is plausible, since GH is released in sleep-linked pulses, but the controlled evidence is thin. Our sermorelin and sleep article goes through the older signals and why supervision matters.

In the lab, the best-cited pattern comes from a 1997 trial in which 19 adults aged 55 to 71 received nightly doses of sermorelin. A later review summarizing it reports that IGF-1 rose significantly by 2 weeks, stayed elevated until 12 weeks and declined at 16 weeks despite continued nightly injections. The same review notes that in another study, IGF-1 did not significantly increase after 2 or 6 weeks of nightly dosing. In short, even the earliest IGF-1 response varies between studies and people.

IGF-1 findings at reported study timepoints

Weeks 5 to 8: the first provider checkpoint

Many clinics describe IGF-1 settling into a steady range after four to six weeks of consistent dosing. This is a practical point for a first review. A provider can compare current symptoms against the baseline recorded before treatment, discuss adherence and decide whether the dose should stay the same.

This is also where consistency matters. Missed doses, irregular timing and poor sleep habits can all blur the picture, and none of them can be seen in a lab value alone.

Months 2 to 3: body composition

Changes in body composition are commonly described at 8 to 12 weeks, but this is the stage where the controlled data are least consistent. A 2016 retrospective chart review in the Journal of Sexual Medicine followed 122 men on sermorelin-based therapy for a median of 499 days. It found no significant change in IGF-1, body weight or body fat percentage, although men whose IGF-1 started below 150 ng/mL showed a trend toward an increase (p=0.08).

The practical reading is that baseline matters. Someone whose IGF-1 starts low has more room to respond than someone already in the mid-range, which is one reason a provider asks for labs and history before prescribing.

Months 3 to 6: skin, hair and longer-term goals

Skin and hair changes are generally discussed at 3 to 6 months, if they appear at all. In the 16-week analog trial summarized above, skin thickness rose in both sexes, while lean mass and some well-being measures improved in men only. Those findings are from one small study, so they describe what was observed in that group and not a promise for any individual.

By this stage, providers typically recheck labs. Testing.com notes that IGF-1 should be rechecked every three to six months during treatment, to confirm that it is rising toward the normal range for the patient’s age without going above it. Fasting glucose is tracked on the same schedule, because GH elevation can affect glucose handling in some people.

IGF-1: The Number Behind the Timeline

IGF-1 is the marker providers use because it reflects GH activity over days to weeks, while GH itself spikes and falls within hours. A realistic pattern looks like this:

  1. Baseline: IGF-1 and related labs are drawn before the first dose.
  2. Early weeks: IGF-1 may begin to rise, though some trials found no significant change at 2 to 6 weeks.
  3. Plateau: Levels may stabilize after roughly one to two months of consistent dosing.
  4. Follow-up: Labs are repeated every three to six months so the provider can confirm IGF-1 stays within an age-appropriate range.

The 1997 pattern, a rise followed by a drift back toward baseline by week 16, is one reason providers review the dose and the plan on a schedule and do not set treatment on autopilot.

What Helps and What Gets in the Way

Factors that commonly influence how a person responds include:

  • Baseline IGF-1 and age. Lower starting levels leave more room for change.
  • Dose timing and consistency. Evening dosing on a regular schedule is the usual protocol.
  • Sleep quality. GH release is tied to sleep, so irregular sleep can limit the effect.
  • Nutrition and exercise. These shape body-composition outcomes independently of any prescription.
  • Concurrent conditions. Untreated thyroid disorders and uncontrolled diabetes are among the situations in which sermorelin is generally not appropriate, along with pregnancy, breastfeeding and active or recent cancer, according to one clinical overview. A provider screens for these before prescribing.

Does Sermorelin Help With Weight Loss?

Weight is the outcome with the least support in the data. The 2016 chart review above found no significant change in body weight. A 2025 Healthline article reports that some research suggests possible improvements in general well-being, lean body mass, insulin sensitivity and libido, while definitive research on anti-aging effects is lacking. Sermorelin is generally discussed as a body-composition and recovery option, not as a weight-loss therapy. Patients whose primary goal is weight management can review the separate Semaglutide program, which is a different class of therapy.

Reading Timelines Critically

Competitor pages often present neat schedules such as “months 4 to 6: peak transformation.” Several practical checks help.

  • Separate anecdote from controlled data. Personal reports cannot establish cause and effect. A guide to telling controlled human research from advertising claims shows how to weigh a claim, which applies to peptides as much as to NAD+ supplements.
  • Check the study population. Many trials were in older adults, in children with GH deficiency or in men with a specific baseline, and may not match your situation.
  • Ask about the product source. A 2026 Scientific American article reports that 40 to 70 percent of thousands of gray-market peptide samples failed basic quality criteria, and about 15 percent of a subset showed endotoxin. Peptides labeled research use only are not intended for human use and fall outside prescription oversight.
  • Look at the regulatory history. Sermorelin (Geref) was FDA-approved in 1997 for children with growth failure. According to one summary, the manufacturer ceased production in 2008 for commercial reasons and the FDA withdrew approval in 2009, with a later Federal Register notice stating that the withdrawal was not for safety or effectiveness reasons. Today, sermorelin for adults is obtained as a compounded prescription, which is why the prescriber and the pharmacy matter. See who prescribes peptides in the U.S. for how location affects the rules.

Safety Checkpoints During the First Months

The 2026 Frontiers review lists injection-site pain, short-term flushing, nausea, dizziness, headache, rare allergic reaction and a short-lived rise in prolactin among the reported safety signals. It also states that long-term safety data are not available. Practical points follow from that:

  • Report persistent headache, dizziness, swelling at the injection site or any signs of allergic reaction to the prescribing provider.
  • Rotate injection sites as instructed; the injection site guide shows where and how.
  • Keep follow-up labs on schedule, including IGF-1 and fasting glucose.
  • For a broader screening framework, see our overview of peptide therapy safety.

Anyone who is pregnant or breastfeeding, has a history of cancer, has thyroid disease or has diabetes should discuss sermorelin with a licensed provider before use, because these conditions affect eligibility.

Our Perspective

We view a results timeline as a monitoring plan, not a promise. Sermorelin works through the body’s own signaling, so the response is gradual and varies from person to person.

That is why we build each plan around provider review. A licensed provider evaluates history and baseline labs, a 503A-style licensed U.S. pharmacy prepares the compounded prescription, and follow-up lets the provider adjust the plan against measured values and not against a generic calendar.

We also believe privacy belongs in the process. Intake, review and ongoing oversight are handled through HIPAA-compliant telehealth, so patients can be supervised without in-office visits and with their health data protected.

For patients who want a supervised, prescription route instead of unregulated research peptides, this structure is the point of the service: a defined starting point, scheduled checkpoints and a prescriber who answers questions.

Jack

Starting Sermorelin Through Vivo

Vivo offers compounded sermorelin by prescription after provider review and approval. Treatment is delivered to the patient’s door from a licensed U.S. pharmacy, with ongoing provider oversight included. Published pricing is $135 per month, or $339 per quarter on the quarterly plan. Patients who also want to compare other options can review the peptide longevity research overview and the comparison of sermorelin and CJC-1295 or sermorelin and ipamorelin.

Questions to Bring to a Provider

  • What are my baseline IGF-1, glucose and thyroid values?
  • Which result would tell us the dose is working, and when will we recheck it?
  • What symptoms should prompt me to contact the provider between reviews?
  • Which licensed pharmacy compounds the prescription?
  • What happens to the plan if my labs stay flat after several months?

FAQ

How soon do you feel the effects of sermorelin?

GH rises within hours of a dose, but most people do not notice anything that quickly. Sleep changes are the earliest effects usually reported, at around 1 to 4 weeks. Other changes, if they occur, are generally described over two to six months, and some people notice little change.

How long does it take sermorelin to raise IGF-1?

In a 1997 trial of a close analog, IGF-1 rose by week 2 and stayed elevated until about week 12. Other studies found no significant IGF-1 change at 2 or 6 weeks. A provider typically rechecks IGF-1 every three to six months to see the actual trend.

Does the short half-life mean the effects wear off in minutes?

No. Sermorelin clears from the blood quickly, but the GH pulse it triggers lasts for hours, and IGF-1 changes build over weeks of regular dosing. The half-life describes how fast the molecule is cleared, not how long a response lasts.

Will sermorelin help with weight loss?

The evidence is limited. A 2016 chart review of 122 men found no significant change in body weight or body fat percentage. Providers generally discuss sermorelin for body composition and recovery goals, and use other therapies when weight loss is the main aim.

What happens if sermorelin is stopped?

Because sermorelin acts through the body’s own signaling and leaves the bloodstream quickly, any hormone changes it produced are expected to fade over time after stopping. Discuss discontinuation with the prescribing provider, who can advise on timing and follow-up labs.

Sources